Literature DB >> 27531383

Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.

Charles W Given1, Barbara A Given1, Cathy J Bradley1, John C Krauss1, Alla Sikorskii1, Eric Vachon1.   

Abstract

Mesh：

Year:  2016        PMID： 27531383      PMCID： PMC5455587          DOI： 10.1200/JOP.2016.012401

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  29 in total

1.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

2.  Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.

Authors:  Peter B Bach; Steven D Pearson
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

3.  Full disclosure--out-of-pocket costs as side effects.

Authors:  Peter A Ubel; Amy P Abernethy; S Yousuf Zafar
Journal:  N Engl J Med       Date:  2013-10-17       Impact factor: 91.245

4.  Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.

Authors:  Xiaobo Zhong; Emerson A Lim; Dawn L Hershman; Carol M Moinpour; Joseph Unger; Shing M Lee
Journal:  J Oncol Pract       Date:  2016-02-23       Impact factor: 3.840

5.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.

Authors:  Sonya Blesser Streeter; Lee Schwartzberg; Nadia Husain; Michael Johnsrud
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

6.  Patient Demands and Requests for Cancer Tests and Treatments.

Authors:  Keerthi Gogineni; Katherine L Shuman; Derek Chinn; Nicole B Gabler; Ezekiel J Emanuel
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

7.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

8.  Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Authors:  Ben Y Durkee; Yushen Qian; Erqi L Pollom; Martin T King; Sara A Dudley; Jenny L Shaffer; Daniel T Chang; Iris C Gibbs; Jeremy D Goldhaber-Fiebert; Kathleen C Horst
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

9.  Self-reported financial burden and satisfaction with care among patients with cancer.

Authors:  Fumiko Chino; Jeffrey Peppercorn; Donald H Taylor; Ying Lu; Gregory Samsa; Amy P Abernethy; S Yousuf Zafar
Journal:  Oncologist       Date:  2014-03-25

10.  Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.

Authors:  Martín Romero; Diana Chávez; Magalí De Los Ríos; Nelson Alvis-Guzmán
Journal:  Biomedica       Date:  2014 Jan-Mar       Impact factor: 0.935
View more
  2 in total

1.  Time to add screening for financial hardship as a quality measure?

Authors:  Cathy J Bradley; K Robin Yabroff; S Yousuf Zafar; Ya-Chen Tina Shih
Journal:  CA Cancer J Clin       Date:  2020-11-23       Impact factor: 286.130

Review 2.  Race, the microbiome and colorectal cancer.

Authors:  Kendra J Royston; Babatunde Adedokun; Olufunmilayo I Olopade
Journal:  World J Gastrointest Oncol       Date:  2019-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.